BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join
back to Directory

OmicEra Diagnostics (acquired by Exact Sciences)

OmicEra Diagnostics logo

Website
https://www.omicera.com/
Founded
2019
Patents
2
Publications
15

Technologies

AI Companies (Drug Discovery)

OmicEra is a leading proteomics and artificial intelligence (AI) startup, dedicated to revolutionize medical diagnostics using high-end mass spectrometry-based proteomics and improve human health. Transparency, reproducible results and open-source software development are deeply integrated into the culture. Their goal is to unravel the secrets fromthe proteome to digitalize a person’s health state.

Proteomics Mass Spectrometry Biomarker Discovery

#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

 

R&D Platform

OmicEra offers cutting-edge MS-based proteome analyses of human samples: ranging from plasma, CSF or urine to any type of FFPE and frozen tissue collection. Powered by innovative AI technology, our results maximize the insight from samples. This helps our clients to improve their research pipelines and discover more reliable and valuable biomarkers.

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.